Alzheimer’s Disease is the most common cause of dementia. Dementia describing a specific set of symptoms such as memory loss, difficulties with problem-solving, language or simply thinking. As the disease progresses, proteins build up in the brain to form structures called ‘plaques’. Eventually there is a break between the nerve cells resulting the death of the cells and a loss of brain tissue. ending in a lack of motor skills. Although progression can vary, typically after diagnosis life expectancy is around three to nine years. Fewer than 3% of people live more than fourteen years.
Management
Medications, psychological intervention and care-giving are all available to AD patients. there are currently 5 different medications on offer for AD each have different results and side affects.
A £5 million project started in the UK last year aims to enable individuals to receive Alzheimer's diagnoses within seconds through the National Health Service (NHS) within the next five years.
The COcoa supplement and multivitamin outcomes study (COSMOS) revealed promising results in the fight against cognitive decline and Alzheimer's disease.
Investigators from Brigham and Women's Hospital, have unveiled a pivotal connection between genetic changes in microglia, immune-regulating brain cells, and the inflammatory response associated with Alzheimer's disease (AD).
A group of researchers around the globe have created a portable, non-invasive device capable of identifying biomarkers associated with Alzheimer's and Parkinson's disease.
A study has revealed that a 1 % decrease in deep sleep each year among individuals aged 60 and older can lead to a 27 % rise in the risk of developing dementia.
Colin Capper, Associate Director of Evidence and Involvement at Alzheimer’s Society, argues that we need improved dementia care and further innovations for people living with dementia today while we wait for the breakthroughs of tomorrow
A new groundbreaking blood test, p-tau217, holds potential as an Alzheimer's disease indicator. When incorporated into a two-step process, it demonstrates exceptional accuracy in detecting or ruling out brain amyloidosis, a crucial early sign.
Dr Deborah Lee from Dr Fox Pharmacy shares evidence on the link between poor mouth care and dementia risk, and the steps needed to promote better oral hygiene.
An experimental Alzheimer's drug called donanemab, developed by Eli Lilly, has demonstrated a slowdown in progression of disease at early stages, according to trial data.
